Breaking News

Curia Expands Capabilities with Access to Touchlight’s Doggybone DNA

Alliance expands Curia’s mRNA manufacturing offering with an additional differentiated source of DNA raw material.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Curia, a CDMO, and Touchlight, a company pioneering enzymatic DNA production, entered an agreement that will provide Curia and its clients streamlined access to Touchlight’s doggybone DNA (dbDNA). The arrangement expands Curia’s mRNA manufacturing offering with an additional differentiated source of DNA raw material that is immediately available to Curia customers. Under the arrangement, Touchlight will directly manufacture dbDNA on behalf of Curia’s customers. Touchlight’s dbDNA is a linear,...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters